Skip to main content

Dr. Csaba P. Kovesdy, M.D.

Nephrology (Kidney) (Nephrology Physician)

At a glance

In the NPI registry since
2005

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Nephrology Physician primary
    VA license 0101230409

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Nephrology (Kidney) per capita by county →

Payments from drug and device companies

In 2025, 2 companies reported 15 payments worth $10,912 in total to this clinician.

By type
Consulting Fee$9,175
Travel and Lodging$1,327
Food and Beverage$410

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Aug 16, 2025Bayer HealthCare Pharmaceuticals Inc.
Aug 16, 2025
Consulting Fee
Kerendia · Cardio-Renal
$7,875
Apr 3, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Apr 3, 2025
Consulting Fee
JARDIANCE · DIABETES
$1,300
Aug 16, 2025Bayer HealthCare Pharmaceuticals Inc.
Aug 16, 2025
Travel and Lodging
Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind
$408
Aug 16, 2025Bayer HealthCare Pharmaceuticals Inc.
Aug 16, 2025
Travel and Lodging
Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind
$285
Aug 15, 2025Bayer HealthCare Pharmaceuticals Inc.
Aug 15, 2025
Travel and Lodging
Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind
$215
Aug 15, 2025Bayer HealthCare Pharmaceuticals Inc.
Aug 15, 2025
Travel and Lodging
Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind
$198
Aug 16, 2025Bayer HealthCare Pharmaceuticals Inc.
Aug 16, 2025
Travel and Lodging
Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind
$130
Aug 16, 2025Bayer HealthCare Pharmaceuticals Inc.
Aug 16, 2025
Travel and Lodging
Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind
$59.70
Aug 17, 2025Bayer HealthCare Pharmaceuticals Inc.
Aug 17, 2025
Travel and Lodging
Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind
$30.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Virginia →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $36,281 in research payments for these studies, mostly to the institutions running them.

  • A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease
    Boehringer Ingelheim International GmbH
  • A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
    AstraZeneca Pharmaceuticals LP
  • A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension
    Novartis Pharmaceuticals Corporation
  • BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chron…
    Bayer HealthCare Pharmaceuticals Inc.
  • BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic
    Bayer HealthCare Pharmaceuticals Inc.
  • A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with R…
    AstraZeneca Pharmaceuticals LP
  • Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
    Csl Behring · Recruiting · NCT05485961

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Nephrology (Kidney) clinicians in Salem

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 17, 2007), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1477553022. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.